Agenus to Present at the 2021 ASCO Annual Meeting
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two presentations at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting poster sessions. The ASCO meeting will be held from June 4 – 8, 2021.
Abstract title: Differentiated activity profile for the PD-1 inhibitor balstilimab
Abstract title: Initial findings of the first-in-human Phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors
Full abstracts will be released on Wednesday, May 19. The 2021 ASCO Annual Meeting will take place virtually on June 4 – 8, 2021.
A Biologics License Application has bee submitted to the U.S. Food and Drug Administration for the use of balstilimab to treat recurrent/metastatic cervical cancer.
AGEN2373 is advancing in a Phase 1 clinical trial against solid tumors.
Agenus Media Relations
Session Details Coming Soon
The Government and YOUR Products/Services